Is compounded tirzepatide legal in 2026?

Compounding a copy of an approved drug is permitted only in limited circumstances, such as a documented shortage or a prescription that requires a change the approved product cannot provide. The shortage basis ended when FDA declared the tirzepatide shortage resolved; providers that still offer compounded tirzepatide rely on other bases, and this page describes them. Whether a specific provider's basis is lawful is a question for regulators and courts, not this site.

Can I get in trouble for buying it?

Enforcement in this area has been directed at compounders and marketers, not patients. That is an observation about past enforcement, not legal advice.

Published August 27, 2026 · updated August 27, 2026 · regulatory and clinical facts last checked 2026-08-27 · medically reviewed by Dr. S. Shuwart, MD on August 27, 2026

Medically reviewed · August 27, 2026

Compounded tirzepatide legal status: shortage end, enforcement and personalised compounding

Why compounded tirzepatide became widely available, what changed when FDA declared the shortage resolved, what enforcement discretion ended and when, and on what basis providers still offer it.

Regulatory facts on this page were checked at the medical review dated above and are re-checked at each review; the status can change, and the provider profiles record what each provider currently says about its own basis for compounding.

Why compounded tirzepatide became widely available

Federal law generally prohibits compounding a drug that is essentially a copy of a commercially available approved drug. The main exception is a drug on FDA’s shortage list: while a drug is in shortage, 503A pharmacies and 503B outsourcing facilities may compound it, subject to their other requirements. Tirzepatide was added to the shortage list in December 2022 as demand for Mounjaro and later Zepbound outran supply. Compounded tirzepatide, sold through telehealth, grew on that basis.

The shortage ends

FDA removed tirzepatide from the shortage list, declaring the shortage resolved, in October 2024, then reconsidered after a compounding trade association sued, and reaffirmed the resolution on 19 December 2024. With the shortage resolved, the shortage exception no longer applied. FDA announced enforcement discretion periods to allow wind-down: for 503A pharmacies until 18 February 2025 and for 503B outsourcing facilities until 19 March 2025. After those dates FDA stated it would apply its normal enforcement approach to compounders producing copies of tirzepatide products.

The litigation

The Outsourcing Facilities Association challenged the shortage determination in federal court in Texas. The court declined to block FDA’s decision, and the enforcement dates above stood. Later developments in that case and any subsequent challenges are checked at each review of this page.

On what basis providers still compound tirzepatide

After the shortage ended, providers and pharmacies that continued to offer compounded tirzepatide generally cited one of two grounds:

A change the approved product cannot provide. Section 503A allows compounding when a prescriber determines that the patient needs a variation, for example a different strength, a different dosing increment, a combination with another ingredient such as vitamin B12, or removal of an excipient. FDA has said it would consider whether such changes produce a significant difference for the patient or are being used to circumvent the prohibition on copies.
Non-commercially available presentations. Where a specific strength or presentation of the approved product is not commercially available, some compounders argue the copy restriction does not apply for that presentation.

Whether a particular provider’s practice falls within these grounds is a matter for FDA, state boards of pharmacy and the courts. FDA has sent warning letters to some telehealth marketers and compounders over unapproved GLP-1 products and marketing claims; the Compounding Disclosure Index records what each provider on this site says about its own basis, and the provider profile links to the source.

What this means for a patient

Availability can change quickly if enforcement changes, and a prepaid multi-month plan carries that risk. The commitment field on every plan record shows whether a plan is prepaid, and the cancellation-terms analysis shows what each provider says happens to unfilled orders.

The semaglutide page follows the same structure with its own dates. The approval page explains what FDA approval covers and why compounded products are outside it.

Questions this page answers

Is compounded tirzepatide legal in 2026?: Compounding a copy of an approved drug is permitted only in limited circumstances, such as a documented shortage or a prescription that requires a change the approved product cannot provide. The shortage basis ended when FDA declared the tirzepatide shortage resolved; providers that still offer compounded tirzepatide rely on other bases, and this page describes them. Whether a specific provider's basis is lawful is a question for regulators and courts, not this site.
Can I get in trouble for buying it?: Enforcement in this area has been directed at compounders and marketers, not patients. That is an observation about past enforcement, not legal advice.

Sources

FDA Drug Shortages database entry for tirzepatide injection (regulator)
FDA: Clarification of policies for compounders as national GLP-1 supply begins to stabilize (regulator)
Federal Food, Drug, and Cosmetic Act sections 503A and 503B (statute)
Outsourcing Facilities Association v. FDA (N.D. Tex.) docket (court)

Educational information, not medical advice. Decisions about GLP-1 medication belong with you and a licensed clinician who knows your history. Compounded medications are not FDA-approved. Report an error.